Staphylococcus aureus, which were resistant to pristinamycin (quinupristin/dalfopristin).
Introduction
Quinupristin and dalfopristin (SYNECID) is a combination of a streptogramin B, quinupristin, with a streptogramin A, dalfopristin, in a 30 : 70 ratio. These compounds are semisynthetic derivatives of naturally occurring pristinamycins, produced by Streptomyces pristinaspiralis. Quinupristin and dalfopristin are more soluble derivatives of pristinamycin ΙA and pristinamycin ΙΙA respectively. [1] They bind with different targets in the peptidyltransferase domain of 23 ribosomal subunit, and inhibit protein elongation steps. Streptogramin A and B act synergistically in vivo; the mixture of the two components is bactericidal and the action is irreversible unlike their individual bacteriostatic activity. [2] The first staphylococcal isolate resistant to the pristinamycin was reported in France, in 1975. [3] Staphylococcal resistance always pertains to dalfopristin, but not necessarily for quinupristin. [4] Quinupristin resistance to Staphylococci is mediated by various mechanisms like methylation of 23s rRNA, [5] inactivation of drug by lactonases, [1] mutation in the L22 ribosomal protein [6] and by efflux of the drug by ABC proteins. [7, 8] Similarly, resistance to dalfopristin is mediated by plasmid genes like vat, vatB, vatC, vatD and satA; [4] staphylococcal genes vga, vgb, vgaB and lsa, which encode ATP-binding efflux proteins that pump type A compounds out of the bacterial cell. [4, 8] A variant of vgaA (vgaAv) carried by a transposon (Tn5406) found in plasmid and/or chromosome of staphylococci was recently characterized. [9] We have isolated two clinical isolates of Blood culture and sensitivity was done as per standard protocol, in the Department of Microbiology, M.L.N. Medical College, Allahabad. The samples were collected in Brain heart infusion broth and periodically sub-cultured on MacConkey agar and blood agar. The colonies that grew were identified to the species level by a battery of biochemical tests. These isolates were tested by Kirby-Bauer disc diffusion method, against a panel of relevant antibiotics, using commercially available antibiotic discs.
[10] The antibiotics tested included ampicillin, amoxycillin-clavulanic acid, amikacin, cephalexin, cephazolin, co-trimoxazole, clindamycin, ciprofloxacin, erythromycin, gentamycin, linezolid, oxacillin, pristinamycin (dalfopristin/ quinupristin), tetracycline, teicoplanin and vancomycin. The MIC of pristinamycin was determined by E-test strips (Hicomb strips from Hi Media Laboratories, Pvt. Ltd., India).
Result and Discussion
The blood samples of both the cases showed growth of MRSA. The MRSA was also resistant to pristinamycin by initial screening, using the Kirby Bauer disk diffusion method. The MICs for dalfopristin/quinupristin among these two isolates were 30 µg ml -¹ and 25 µg ml -¹. Although this test is not approved by the NCCLS, there are numerous studies which showed that E-test disk diffusion and broth micro dilution methods were comparable in accuracy for the susceptibility testing for MRSA and vancomycin resistant Enterococcus (VRE) against linezolid and quinupristin/dalfopristin. [11] Earlier studies have shown very low MIC; MIC 90 of 1-2 mg l -¹ for MRSA and 0.5 -2 mg l -¹ for CONS, Streptococcus pneumoniae, Streptococcus viridans and Streptococcus pyogenes. Earlier studies have reported that almost all isolates of MRSA and MRCONS are susceptible to dalfopristin/ quinupristin. [11, 12] However, our findings were in contrast to the earlier studies done in this field.
Infections due to gram-positive cocci are becoming more difficult to treat because of rapid emergence of antibiotic resistance and their dissemination in the population. Earlier observations have demonstrated that dalfopristin/quinupristin have good activity against MDR gram-positive cocci and are a promising therapeutic option in the era of rapidly increasing resistance in almost all parts of the world.
It is very interesting to find pristinamycin resistant Staphylococcus aureus in our country, where pristinamycin is not available in vivo for patient management. Pristinamycin is being used only as a research tool, by using antibiotic discs procured from a commercial source.
In the present study, the Staphylococcal isolates were found resistant to three or more antimicrobial agents among the panel of antibiotics tested. Therefore, they were defined as MDR Staphylococcal isolates. It may be postulated that resistance against pristinamycin is plasmid mediated. This plasmid may also contain genes conferring resistance against other commonly used antibiotics. Probably this gene was in a repressed state and was expressed on first exposure to the drug. Various genes have been identified which are responsible for causing streptogramin resistance, like erm, vgb A, vgb B, and msr genes.
More clinical isolates need to be tested against this antibiotic, so that the exact percentage of primary in vitro resistance can be known. Genetic studies for the responsible gene(s) should be done. After the above two cases, we are now storing all the pristinamycin resistant GPC isolates in our laboratory for further studies. We have isolated other pristinamycin resistant GPCs also, from specimens other than blood. After complete comprehensive studies on all such isolates have been done to find out the exact percentage of primary in-vitro resistance against this drug, in this part of our country. Thus, on the basis of our observation, it is advisable that more comprehensive region-wise laboratory work is done, before advocating this drug for empirical therapy for MDR GPC infections.
